Certara (CERT) Q4 2025 earnings review
Growth Stalls as New CEO Triggers a Strategic Reset
Certara closed FY25 with a whimper, as Q4 revenue growth decelerated sharply to 3% YoY and Adjusted EBITDA shrank 3%. The narrative shifted dramatically under newly appointed CEO Jon Resnick: instead of blaming 'macro headwinds' for underperformance, management is now pointing to internal 'execution challenges' that caused Software Bookings to abruptly contract 6% YoY. Consequently, 2026 has been designated a 'year of transition,' with revenue growth guided to an anemic 0-4%. While a 17% rebound in Services Bookings provided a lone bright spot, a swing to a GAAP net loss and stagnant earnings outlook suggest Certara's core growth engine is broken.
🐂 Bull Case
Services Bookings surged 17% YoY to $99.1M in Q4. This reversed the alarming 9% contraction seen in Q3, driven by broad-based growth across all customer tiers.
Despite the severe revenue deceleration expected in 2026, Adjusted EBITDA margin guidance remains Stable at 30-32%, proving that the company can maintain cost discipline during its transition.
🐻 Bear Case
Software Bookings shrank 6% YoY. Management explicitly blamed execution challenges, undermining the previous narrative that their software segment was immune to pharma budget tightening.
FY26 revenue guidance of 0-4% growth represents a massive deceleration from the 9% growth achieved in FY25 and historical 10%+ targets. The recovery will likely take multiple quarters.
⚖️ Verdict: 🔴
Bearish. The sudden contraction in Software Bookings and the 'transition year' guidance indicate structural sales issues that cannot be easily fixed. Stable margins do not offset a collapsing top-line growth algorithm.
Key Themes
Software Narrative Collapses
In Q2 and Q3, management explicitly blamed software softness on 'timing issues' and insisted demand remained robust. The Q4 print shattered this narrative: Software Bookings declined 6% YoY to $56.1M. More importantly, management shifted the blame from macro conditions to 'execution challenges.' This marks a severe Reversing trend for a segment that was growing 38% just a year ago and forces investors to question the company's internal sales capabilities.
Services Segment Bounces Back
Reversing the severe weakness seen in Q3 (when bookings fell 9%), Services Bookings surged 17% YoY to $99.1M in Q4. Management cited growth across large, mid-sized, and small customers. However, this bookings strength hasn't hit the P&L yet, as recognized Services Revenue actually dropped 1% YoY to $57.3M. Converting this backlog efficiently will be vital in FY26.
The 'Transition Year' Growth Shock
The introduction of new CEO Jon Resnick comes with a total reset of expectations. Management guided FY26 revenue growth to an anemic 0-4%. This is a massive Decelerating trend compared to 9% growth in FY25. Resnick stated 2026 will be a year of 'investment to put the right people, processes, and structure in place,' signaling a deeper operational rebuild than the market anticipated.
Stable End Markets Expose Internal Flaws
CFO John Gallagher noted that the company expects 'end markets to remain stable' in 2026. This contradicts previous quarters where management repeatedly cited Tier 1 pharma sluggishness and biotech funding constraints as primary headwinds. If the macro market is stable but Certara is only guiding to 0-4% growth, it confirms the recent underperformance is largely a self-inflicted execution wound.
Continued AI & Product Innovation
Despite commercial stumbles, Certara is leaning heavily into its product pipeline. The ongoing rollout of CertaraIQ and the Non-Animal Navigator—designed to replace animal testing for monoclonal antibodies following FDA guidance—remain core long-term drivers. Management affirmed that R&D investments will be protected through the 2026 transition.
Other KPIs
Reversing trend. Net income swung from a $6.6M profit a year ago to a $5.9M loss. The $12.5M deterioration was driven by a $7.0M spike in employee-related costs, $0.8M in higher software expenses, and $0.7M in transaction expenses tied to a term loan refinancing.
Accelerating trend. Despite the GAAP net loss of $1.6M for the full year, operating cash flow grew nicely from $80.5M in FY24 to $96.3M in FY25. This strong cash conversion supported the execution of $42.6M in share repurchases over the year without stressing the balance sheet.
Guidance
Decelerating. A severe step-down from the 9% reported growth in FY25. Based on FY25 revenue of $418.8M, this implies a range of roughly $418.8M to $435.6M, effectively pausing the company's historical growth trajectory.
Stable. The guide perfectly brackets the 32.1% achieved in FY25. It shows that while management is rebuilding the sales engine and suffering top-line stagnation, they are strictly defending profitability and not letting the 'transition year' destroy the bottom line.
Stable. The midpoint of $0.46 is practically flat versus the $0.44 delivered in FY25 and $0.45 in FY24. Earnings growth is completely stalled until the top-line re-accelerates.
Key Questions
Software Execution Post-Mortem
You specifically cited 'execution challenges' for the 6% decline in Q4 Software Bookings. Were these sales force turnover issues, integration problems with Chemaxon, or competitive losses?
Market Share Dynamics
With the CFO expecting 'stable' end markets but revenue guidance collapsing to 0-4%, how much market share do you expect to lose to competitors during this 'year of transition'?
Services Backlog Conversion
Services Bookings grew an impressive 17% in Q4, yet recognized Services Revenue declined 1%. What is the duration of the current backlog, and when will this bookings strength visibly hit the P&L?
Capital Allocation Pause
You executed $42.6M in share repurchases in 2025. Given the depressed growth outlook and 'investment year' narrative, will buybacks be paused to fund operational restructuring?